Autoantibody detection in scleroderma patients. Diagnostic and analytical performances of a new coupled particle light scattering immunoassay

Clinical and Experimental Rheumatology

Volumn 20, Issue 1, 2002, Pages 45-51

  Bizzaro, N ^a   Bonelli, F ^a   Tonutti, E ^a   Villalta, D ^a   Tozzoli, R ^a  

^a Ospedale Civile   (Italy)

Author keywords

Anti centromere antibodies; Autoimmune disease; CENP B; Light scattering immunoassay; Systemic sclerosis; Topoisomerase I

Indexed keywords

AUTOANTIBODY; CELL ANTIGEN; CENTROMERE ANTIBODY; DNA TOPOISOMERASE; ENZYME ANTIBODY; RECOMBINANT DNA; RECOMBINANT PROTEIN;

ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; BACULOVIRUS EXPRESSION SYSTEM; BLOOD SAMPLING; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEVICE; GENE EXPRESSION SYSTEM; HUMAN; IMMUNOASSAY; LIGHT SCATTERING; LYME DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROKARYOTE; RHEUMATIC DISEASE; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS; VIRUS INFECTION; VOLUNTEER;

AUTOANTIBODIES; AUTOANTIGENS; CENTROMERE PROTEIN B; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA TOPOISOMERASES, TYPE I; DNA-BINDING PROTEINS; HUMANS; IMMUNOASSAY; SCATTERING, RADIATION; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY;

EID: 0036200914     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients
2. Topoisomerase I (Scl-70) autoantibodies
3. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma
4. Autoantibody to centromere (kinetochore) in scleroderma sera
5. Three human chromosomal auto antigens are recognized by sera from patients with anticentromere antibodies
6. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients
7. Serological markers in progressive systemic sclerosis: Clinical correlation
8. Clinical significance of antinuclear antibodies in systemic rheumatic diseases
9. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis
10. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis
11. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: A six years follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting
12. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study
13. Sensitivity and specificity of immunological methods for the detection of anti-topoisomerase I (Scl70) autoantibodies: Results of a multicenter study
14. Autoantibodies to topoisomerase I (Scl-70): Analysis by gel diffusion, immunoblot, and enzyme-linked immunosorbent assay
15. Development and comparative evaluation of immunoblot assays for detecting autoantibodies to Scl 70 and Jo 1 antigens in serum
16. An enzyme-linked immunosorbent assay for the autoantibodies against the nuclear antigen Scl-70
17. Development of the antinuclear and anticytoplasmic antibody consensus panel by the Association of Medical Laboratory Immunologists
18. Test performance in systemic sclerosis: Anti-centromere and anti-Scl-70 antibodies
19. A review of methods available for the identification of both organ-specific and non-organ specific autoantibodies
20. A critical evaluation of enzyme immunoassay for detection of antinuclear autoantibodies of defined specificities. I. Precision, Sensitivity, and Specificity
21. Evaluation of commercial ELISA, CIE and IB assays for the detection of anti-topoisomerase I antibodies: Results of a multicentric study
22. Specificity of anti-Scl-70 antibodies in scleroderma: Increased sensitivity of detection using purified DNA topoisomerase I from calf thymus
23. Detection of anti-topoisomerase I antibodies using a full length human topoisomerase I recombinant protein purified from a baculovirus expression system
24. Autoantibody testing for connective tissue disease. Comparison of immunodiffusion, immunoblot, and enzyme immunoassay
25. Comparison of three commercially available enzyme immunoassay for the screening of autoantibodies to extractable nuclear antigens
26. Detection of anti-DNA topoisomerase I by an enzyme-linked immunosorbent assay using overlapping recombinant polypeptides
27. Copalis Technology
28. Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients
29. Analysis of an immunodominant epitope of topoisomerase I in patients with systemic sclerosis
30. An immunodominant epitope on DNA topoisomerase I is conformational in nature
31. Autoantibodies against topoisomerase I detected with the natural enzyme and overlapping recombinant peptides
32. Identification of a universal B cell epitope on DNA topoisomerase I, an autoantigen associated with scleroderma
33. cDNA cloning of human topoisomerase I. Catalytic activity of a 67.7 kDa carboxyl-terminal fragment
34. A recombinant topoisomerase I ELISA: Screening for IgG, IgM and IgA anti-topo I autoantibodies in human sera
35. An antigenic region of topoisomerase I in DNA polymerase chain reaction-generated fragments recognized by autoantibodies of scleroderma patients
36. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
37. Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders
38. Receiver-operating characteristics (ROC) plots: A fundamental valuation tool in clinical medicine
39. Coupled particle light scattering (Copalis®) technology for the performance of immunoassay
40. Variability between methods to determine ANA, anti-dsDNA and anti-ENA autoantibodies: A collaborative study with the biomedical industry
41. Sensitivity of commercial reagents for the detection of anti-ENA antibodies
42. The Consensus Workshop for the Detection of Autoantibodies to Intracellular Antigens in Rheumatic Diseases: 1989-1992
43. Comparison between E. coli and Baculovirus-expressed recombinant topoisomerase I antigens for the detection of autoantibodies in scleroderma patients
44. Autoantibodies to scleroderma-associated antigens
45. A case of systemic sclerosis with anti-centromere, antitopoisomerase I, and anti-U1RNP antibodies
46. Are ACA and Scl-70 antibodies mutually exclusive?
47. A patient with systemic sclerosis, severe cytopenias and the simultaneous presence of anticentromere and anti-Scl170 antibodies
48. Coincidence of anti-topoisomerase I and anti-centromere antibodies in patients with systemic sclerosis
49. Association of anticentromere and anti-Scl70 antibodies in scleroderma: Report of two cases
50. Coexistence of anti-centromere and anti-topoisomerase I antibodies in a patient with silica-induced scleroderma